Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4

Keyphrases

• Myasthenia Gravis 100%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 100%
• CD40 Ligand (CD40L) 100%
• Th1 Differentiation 100%
• Experimental Autoimmune 75%
• Acetylcholine Receptor (AChR) 50%
• Anti-CD40 50%
• Autoimmune Disease 25%
• Costimulatory Molecules 25%
• Nicotinic Acetylcholine Receptor (nAChR) 12%
• Specific Response 12%
• Experimental Autoimmune Myasthenia Gravis 12%
• Splenocytes 12%
• Autoantigen 12%
• Humoral Response 12%
• Delayed Hypersensitivity 12%
• Cytokine Profile 12%
• Adoptive Transfer 12%
• Disease Suppression 12%
• Inflammatory Cytokines 12%
• T-cell Mediated 12%
• Cellular Factors 12%
• Autoimmune Process 12%
• Specific Immune Response 12%
• Regulatory Cells 12%
• Disease Pathogenesis 12%
• Chronic Stage 12%
• Response Types 12%
• Autoreactive B Cells 12%
• Clinical Progression 12%

Immunology and Microbiology

• CTLA-4 100%
• Downregulation 100%
• Experimental Autoimmune Myasthenia Gravis 100%
• CD40 Ligand 100%
• Upregulation 100%
• Autoimmune Disease 25%
• Myasthenia gravis 25%
• Immunotherapy 12%
• T Cell 12%
• Immune Response 12%
• Autoantigen 12%
• Splenocyte 12%
• Autoimmunity 12%
• Humoral Immunity 12%
• B Cell 12%
• Delayed Hypersensitivity 12%
• Nicotinic Acetylcholine Receptor 12%
• Cytokine 12%
• Proinflammatory Cytokine 12%
• Regulatory Cell 12%